Relationship between Circulating FGF21 Concentrations and the Severity of Coronary Artery Damage in Subjects with Cardiovascular Disease

Park, Sung Don; Bae, Kwi-Hyun; Choi, Youn‐Hee; Jeon, Jae‐Han; Seo, Jung Beom; Kim, Nam Kyeun; Kim, Chang-Yeon; Kim, Sung Woo; Lee, Won Kee; Kim, Jung Guk; Lee, Inkyu; Lee, Jang Hoon; Park, Keun-Gyu

doi:10.12997/jla.2018.7.1.42

Cited by 4 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study of 417 patients, the serum FGF21 levels of the patients with CAD and without CAD were similar regardless of the presence of diabetes, and there was no association between the serum FGF21 levels and the severity of CAD defined by the number of stenotic vessels and segments (20). In Park et al (21) study, no relationship was found between serum FGF21 levels and the severity of CAD determined by SYNTAX scores. In another study, Kim et al (22) initially observed a sig-nificant correlation between serum FGF21 levels and GENSINI and EXTENT scores of 120 patients; however, in the final analysis, they found that there was no relationship between FGF21 levels and the risk scores in diabetic patients (r = 0.332, p = 0.055; and r = 0.296, p = 0.084, respectively).…”

Section: Discussionmentioning

confidence: 90%

Is serum fibroblast growth factor 21 associated with the severity or presence of coronary artery disease?

Nar¹,

Sanlialp²,

Nar³

et al. 2022

J Med Biochemistry

View full text Add to dashboard Cite

Aim: Recent studies have shown that increased circulating concentrations of fibroblast growth factor 21 (FGF21) are associated with obesity, metabolic disorder, and atherosclerosis. However, the studies which investigate the relationship between serum FGF21 levels and coronary artery disease (CAD) include conflicting data. In this study, we planned to investigate the role of FGF21 in CAD development and CAD severity. Method: Seventy-eight patients with stable angina pectoris (SA) (lesion positive) and 40 control patients (lesion negative) with similar cardiovascular risk factors who underwent coronary angiography were included in the study. Serum FGF21 levels were measured by ELISA method. CAD severity was evaluated by using SYNTAX and GENSINI risk scores. Results: Although there was a statistically significant difference between serum FGF21 levels in the SA and the control groups [101.18 ± 141.62 vs. 47.93 ± 58.74 pg/mL; p = 0.03], no correlation was found between the SYNTAX (r = 0.146 and p = 0.134) and GENSINI (r = 0.211 and p = 0.084) scores with serum FGF21 levels. The SA group had lower serum HDL-C levels (41.57 ± 11.40 vs. 54.90 ± 34.47; p = 0.02). There was a significant and negative relationship between serum FGF21 and serum HDL-C levels in correlation analysis (r = - 0.272; p = 0.026). Conclusion: The serum FGF21 levels are different between SA diagnosed and control patients. FGF21 may be a marker for CAD diagnosis, but not for the evaluation of CAD severity. To the best of our knowledge, this is the first study to evaluate coronary artery disease severity together with a lipid profile.

show abstract

Section: Discussionmentioning

confidence: 90%

Is serum fibroblast growth factor 21 associated with the severity or presence of coronary artery disease?

Nar¹,

Sanlialp²,

Nar³

et al. 2022

J Med Biochemistry

View full text Add to dashboard Cite

show abstract

“…The determination of whether FGF21 has clinical significance as a biomarker is complicated by several potential confounding circumstances. The study conducted by Park et al [ 20 ] could not find any correlation between serum FGF21 levels and the severity of CAD as evaluated by SYNTAX scores.…”

Section: Discussionmentioning

confidence: 89%

The Correlation Between Serum Fibroblast Growth Factor 21 and the Severity and Occurrence of Coronary Artery Disease

Sinha,

Prakash,

Keshari

et al. 2024

Cureus

View full text Add to dashboard Cite

Background: The burden of cardiovascular diseases (CVDs) is increasing worldwide with CVD being one of the leading causes of death, including atherosclerosis, myocardial infarction, cardiomyopathy, and heart failure (HF). Fibroblast growth factor 21 (FGF21) is an endocrine hormone that regulates carbohydrate and lipid metabolism. It exerts direct effects on the cardiovascular system and can serve as an early indicator of CVDs. FGF21's therapeutic properties include reducing obesity, dyslipidaemia, and hyperglycemia, which can help treat metabolic disorders, autophagy, and apoptosis. Atherosclerosis is developed due to chronic inflammatory conditions, and the immune system's reaction to oxidized lipoproteins is mainly responsible for the development of atherosclerosis. FGF21's precise role in the pathogenesis of coronary artery disease (CAD) remains elusive. Aim: This study aimed to assess the role of FGF21 in predicting the severity and magnitude of CAD in individuals diagnosed with stable angina pectoris (SAP). Materials and methods: A prospective cross-sectional study was conducted on 110 consecutive patients with SAP reported to the cardiology department of the Indira Gandhi Institute of Medical Sciences (IGIMS), Patna, India. They were divided into two groups based on coronary angiography findings. Control groups included patients not showing any atherosclerotic lesions and case groups with atherosclerotic lesions. The SYNTAX score is a grading system that measures the location and complexity of coronary arteries using anatomical principles. The Gensini score assessment technique was employed to determine the severity of CAD. We compared serum FGF21 levels,left ventricular ejection fraction (LVEF), and inflammatory biomarker C-reactive protein (CRP) levels between the two groups. Moreover, we examined the correlation between the serum FGF21 level and the SYNTAX and Gensini scores. The statistical analysis was done using Version 23.0 of SPSS Statistics. P-values below 0.05 were considered statistically significant. Results: The study found that the case group had a higher average age and a higher proportion of male patients. The case group had considerably higher levels of FGF21 (166.59 ± 94.49791 pg/mL) compared to the control group (54.13 ± 48.467 pg/mL) (p=0.034). The LVEF exhibited a significant difference between the case and control groups, with mean values of 50.3056 ± 7.8242% and 56.078 ± 5.3987%, respectively (p=0.031). CRP levels were comparable in both groups. The case group had mean values of SYNTAX and Gensini scores of 23.19±7.43 and 50.03±27.30, respectively. We found that there was no statistically significant association between the risk assessments for CAD severity and the levels of serum FGF21 (correlation coefficient r=0.14070, p>0.05, and r=0.206415, p>0.05, respectively) Conclusions: FGF21 is gaining recognition as a prospective addition to the FGF family, potentially playing a significant role in cardiovascular disease, particularly ather...

show abstract

“…In recent years, many observational studies have reported that FGF21 plays a role in metabolic homeostasis [72]. Berglund et al [73] showed that subcutaneous administration of FGF21 for 3-7 days signi cantly reduced fasting blood glucose, triglyceride and insulin levels, thereby improving glucose metabolism in animal models of diabetes.…”

Section: Fgf21mentioning

confidence: 99%

Cross-talk between hepatokines as Liver indused-exercise factors and organokines

rad

2023

Preprint

View full text Add to dashboard Cite

Exercise not only improves the capacity of the skeletal muscles that perform contractions, but also provides health benefits and prevents a number of chronic diseases caused by physiological and biological changes throughout the body. For decades, intensive research has been carried out into the “exercise factors” that mediate these positive effects. In particular, skeletal muscle tissue has been studied as a source of circulating exercise factors and several myokines have been identified. However, Exercise also affects other tissues. The liver plays an important role in the tissues that store and use energy as well as it is very active during exercise and ensures the maintenance of energy homeostasis. Recently, a novel group of Liver indused-exercise factors termed hepatokines has emerged. Hepatokines can act in an autocrine/paracrine manner on the liver and as endocrine factors on brain, endothelium, adipose tissue, pancreas, heart, intestine, and skeletal muscle. In most cases, an acute bout of exercise increases the systemic concentration of hepatokines (FGF21, ANGPTL4, Follistatin, Selenoprotein P, HSP72 ,IGFBP, fetuin-A, fetuin-B, Hepassocin, Activin E, Chemerin, Adropin) and this factors released from the liver and increased in the bloodstream during or in the recovery after an exercise bout. It should be noted that in addition to liver tissue, there are also other hepatokines secreted and released by other tissues such as brain, adipocytes, intestine, heart, osteoblasts and melanoma. In this narrative review, we evaluate this new group of exercise factors focusing on the regulation and potential function in exercise metabolism and adaptations .These hepatokines may convey some of the beneficial whole-body effects of exercise and cross-talk with organokines and could ameliorate metabolic diseases, such as obesity or type 2 diabetes.

show abstract

Relationship between Circulating FGF21 Concentrations and the Severity of Coronary Artery Damage in Subjects with Cardiovascular Disease

Cited by 4 publications

References 20 publications

Is serum fibroblast growth factor 21 associated with the severity or presence of coronary artery disease?

Is serum fibroblast growth factor 21 associated with the severity or presence of coronary artery disease?

The Correlation Between Serum Fibroblast Growth Factor 21 and the Severity and Occurrence of Coronary Artery Disease

Cross-talk between hepatokines as Liver indused-exercise factors and organokines

Contact Info

Product

Resources

About